Aignostics Launches HETA Clinical AI to Cut Failed Molecular Tests
Berlin – October 16, 2026 -- Aignostics has launched HETA Clinical, a family of pan-cancer AI products aimed at the 10% to 20% of molecular tests that pathologists estimate fail because tissue contains too little tumor.
The first four products analyze whole slide H&E images across the pathology workflow, from intake and evaluation through to molecular testing. The company says the suite helps labs prioritize cases, cut turnaround time and confirm sufficient tumor content before molecular testing begins.
Four products target slide quality, tumor presence, mitoses and cellularity
HETA Quality Control measures slide quality before analysis and identifies a range of quality issues. HETA Tumor Detect annotates tumor regions and flags cases likely to contain tumor at scanning, so those cases are read first and additional stains can be ordered at intake.